Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Update

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) was the target of a large decline in short interest during the month of February. As of February 13th, there was short interest totaling 8,673 shares, a decline of 35.7% from the January 29th total of 13,496 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily volume of 61,109 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily volume of 61,109 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.2% of the shares of the company are sold short.

Kiora Pharmaceuticals Stock Performance

Kiora Pharmaceuticals stock traded down $0.01 during midday trading on Friday, hitting $2.09. 6,175 shares of the company were exchanged, compared to its average volume of 48,069. The business has a fifty day simple moving average of $2.12 and a two-hundred day simple moving average of $2.33. The firm has a market capitalization of $7.69 million, a PE ratio of -1.00 and a beta of -0.82. Kiora Pharmaceuticals has a fifty-two week low of $1.76 and a fifty-two week high of $4.18.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Two Sigma Investments LP purchased a new stake in shares of Kiora Pharmaceuticals during the 3rd quarter worth about $33,000. Renaissance Technologies LLC raised its holdings in Kiora Pharmaceuticals by 71.0% in the 4th quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock worth $42,000 after purchasing an additional 8,800 shares during the period. Citadel Advisors LLC purchased a new position in Kiora Pharmaceuticals during the third quarter worth approximately $125,000. Alyeska Investment Group L.P. acquired a new stake in Kiora Pharmaceuticals in the fourth quarter valued at approximately $152,000. Finally, DRW Securities LLC raised its stake in shares of Kiora Pharmaceuticals by 199.2% during the 4th quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock worth $217,000 after buying an additional 73,417 shares during the period. Hedge funds and other institutional investors own 76.97% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a report on Wednesday, January 28th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Kiora Pharmaceuticals currently has an average rating of “Hold” and an average target price of $10.00.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.